ArticleParkinson's disease2015
Salivary acetylcholinesterase activity is increased in Parkinson's disease: a potential marker of parasympathetic dysfunction.
Article in Parkinson's disease, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 52 citations in OpenAlex.
- Pooled it
- Parkinson's Disease and Salivary Issues: A Survey.Gerodontology · 2026Article
- Oral health implications in Parkinson's disease.NPJ Parkinson's disease · 2025Review
- Predictors of drooling severity in people with Parkinson's disease.Journal of neurology · 2025Article
- Precision Enzyme: Targeted Drug Discovery in Neurodegenerative Disorders.Protein and peptide letters · 2025Review
- Early diagnosis of Parkinson's disease: biomarker study.Frontiers in aging neuroscience · 2025Review
- Assessment of acetylcholinesterase activity in CD9-positive exosomes from patients with Parkinson's disease.Frontiers in aging neuroscience · 2024Article
- Physiological ischemic training improves cardiac function through the attenuation of cardiomyocyte apoptosis and the activation of the vagus nerve in chronic heart failure.Frontiers in neuroscience · 2023Article
- Salivary Biomarkers: Noninvasive Ways for Diagnosis of Parkinson's Disease.Neurology research international · 2023Review
- Basics for the potential use of saliva to evaluate stress, inflammation, immune system, and redox homeostasis in pigs.BMC veterinary research · 2022Review
- Salivary inflammatory biomarkers are predictive of mild cognitive impairment and Alzheimer's disease in a feasibility study.Frontiers in aging neuroscience · 2022Article
- Acetylcholinesterase Inhibitors in the Treatment of Neurodegenerative Diseases and the Role of Acetylcholinesterase in their Pathogenesis.International journal of molecular sciences · 2021Review
- Changes in Saliva Analytes in Dairy Cows during Peripartum: A Pilot Study.Animals : an open access journal from MDPI · 2021Article
- The Role of Salivary Biomarkers in the Early Diagnosis of Alzheimer's Disease and Parkinson's Disease.Diagnostics (Basel, Switzerland) · 2021Review
- The Evolving Landscape of Exosomes in Neurodegenerative Diseases: Exosomes Characteristics and a Promising Role in Early Diagnosis.International journal of molecular sciences · 2021Review
- Salivary Heme Oxygenase-1: A Potential Biomarker for Central Neurodegeneration.Journal of central nervous system disease · 2021Article
- Hydroxypropyl-β-cyclodextrin as an effective carrier of curcumin - piperine nutraceutical system with improved enzyme inhibition properties.Journal of enzyme inhibition and medicinal chemistry · 2020Article
- Traumatic Brain Injury and Stem Cells: An Overview of Clinical Trials, the Current Treatments and Future Therapeutic Approaches.Medicina (Kaunas, Lithuania) · 2020Review
- Salivary Biomarkers for Alzheimer's Disease and Related Disorders.Neurology and therapy · 2019Review
- Changes in Saliva Analytes Correlate with Horses' Behavioural Reactions to An Acute Stressor: A Pilot Study.Animals : an open access journal from MDPI · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction. Decreased salivary flow and xerostomia are frequent findings in Parkinson's disease (PD), possibly caused by alterations in the parasympathetic tonus. Here we explore salivary acetylcholinesterase (AChE) activity as a potential biomarker in PD. Methods. We measured salivary flow, AChE activity, and total protein concentration in 30 PD patients and 49 healthy controls. We also performed exploratory correlation analyses with disease duration, motor symptom severity, autonomic complaints, and other nonmotor symptoms. Results. PD patients displayed significantly decreased salivary flow rate, significantly increased salivary AChE activity, and total protein concentration. Importantly, the AChE activity/total protein ratio was significantly increased in PD patients, suggesting that increased AChE activity cannot be explained solely by upconcentration of saliva. The Unified PD Rating Scale (UPDRS) score displayed significant correlation with total salivary protein (P = 0.002) and near-significant correlation with salivary flow (P = 0.07). Color vision test scores were also significantly correlated with AChE activity (P = 0.04) and total protein levels (P = 0.002). Conclusion. Salivary AChE activity is increased in PD patients compared to healthy controls. Future studies are needed to elucidate whether this parameter reflects the extent of neuronal damage and parasympathetic denervation in the salivary glands of PD patients.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.